With the exponential increase of interest in dry eye or ocular surface disease (OSD) among physicians and the industry, we are fortunate to have access to exciting new diagnostic and imaging technology as well as new treatment options and therapeutics for some of our most frustrated patients.
I was once characterized as an “information parasite” by a colleague. I must admit that I do troll the Internet, particularly Pub Med, for new, intriguing information especially when its related to one of my two favorite ocular phenomenon that are pseudoexfoliation syndrome and the lid margin.
First acquired during birth from the mother and rapidly thereafter from the surrounding environment, bacteria colonize our conjunctiva and lacrimal systems. It is estimated that more than 200 species of bacteria commonly inhabit the human conjunctival mucosa.
A common barrier to many practitioners is the concern that their practice does not have the patient foundation to make investment in the services economically profitable. I assure you that OSD management will profit the patient in many ways that includes clearer, more comfortable vision, enhancing their productivity and overall wellbeing.
While there are a myriad of associated concerns due to ocular surface inflammation, a few eyelash-related complications of note are trichiasis, acquired distachiasis, local madarosis, and poliosis. Each of these is in some way connected to dry eye.